Tsutani Y, et al. - In this multicenter phase II study including chemotherapy-naïve patients with stage IIIB–IV or recurrent nonsquamous non-small cell lung cancer (NSCLC), researchers assessed the safety and efficacy of induction chemotherapy with bevacizumab followed by maintenance chemotherapy with bevacizumab. Participants received 4 cycles of induction cisplatin (75 mg/m²), pemetrexed (500 mg/m²), and bevacizumab (15 mg/kg) followed by maintenance with pemetrexed (500 mg/m²) and bevacizumab (15 mg/kg) until disease progression. According to findings, induction chemotherapy with cisplatin, pemetrexed, and bevacizumab followed by maintenance chemotherapy with pemetrexed and bevacizumab was proved to be safe and effective in patients with advanced or recurrent nonsquamous NSCLC, regardless of their epidermal growth factor receptor (EGFR) mutation status, with a 70.6% objective response, and 97.1% disease control rate, 10.8 and 48.0 months of median progression-free survival and overall survival, respectively.